Baseline imaging may predict teprotumumab response

Total rectus volume is predictive of proptosis reduction following treatment with teprotumumab in patients with thyroid eye disease (TED), according to a study that examined potentially predictive baseline imaging characteristics.

Of the 25 patients included, 17 (68%) achieved ≥2 mm reduction in proptosis after treatment with teprotumumab. These patients had significantly greater medial rectus, inferior rectus, superior rectus, and total rectus volume compared to those who did not achieve ≥2 mm reduction in proptosis.

Total rectus volume was the only significant predictor of ≥2 mm reduction in proptosis following treatment with teprotumumab.

Reference
Roelofs K, et al. Radiologic Predictors of Response to Teprotumumab. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium.